Regentis Biomaterials Ltd. (RGNT)
RGNTAMEXIndustrial Specialties
$1.19
-0.0400 (-3.25%) today
Closed, Nov 16, 3:59 PM ET
- Market cap
- $8.64m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.16 to $15.50
- Average volume
- –
- Previous close
- $1.23
Earnings
Next report
Financials
| Quarter | Dec 2022 |
|---|---|
| Revenue | – |
| Gross profit | – |
| Operating income | -$1.41m |
| Net income | -$1.45m |
News
5 latest- Top Biotech Gainers: CANF Climbs, RGNT Gears Up For Europe Launch, RNAZ, ELTX On Watch RTTNews · Jul 1, 2026
- Top Biotech Gainers: RGNT Withdraws F-1 Filing, FDA Clears CUPR's Maggot Therapy, MYO On Watch RTTNews · Jun 15, 2026
- Top Biotech Gainers: RGNT Walks The Talk, ELOX Returns To Relevance, ALHC Rallies, LRMR On Watch RTTNews · Jun 9, 2026
- Regentis Surges After Plans To Start European Surgeon Training In Q3 For Advancing GelrinC Launch RTTNews · Jun 9, 2026
- Pre-Market Movers: RGNT, FEED, BYAH Swing Big RTTNews · Jun 9, 2026
The company
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis' Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis' lead product GelrinC(R), is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC(R) aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.
- Sector
- Health Care
- Industry
- Industrial Specialties
- Exchange
- AMEX
- Region
- Middle East
- Website
- regentis.co.il
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.